# Short CV

**Name:** **GARCIA PAVIA, PABLO**
E-mail: pablogpavia@yahoo.es; pablogpavia@cnic.es
ORCID: 0000-0002-5470-2257
Date: 1st March 2026

## Education/Training:

| Institution and Location | Degree | Year |
|---|---|---|
| Universidad Autónoma Madrid, Spain | MD | 2003 |
| Clínica Puerta de Hierro, Spain | Specialist in Cardiology | 2009 |
| Universidad Autónoma Madrid, Spain | PhD | 2011 |
| IESE-Universidad de Navarra, Spain | PADIIT – Management degree in research institutions | 2018 |

## Main Positions:

**Head, Heart Failure & Inherited Cardiac Diseases Unit.** Start: June 2009

National Referral unit designated by the Spanish Ministry of Health (CSUR). European Reference center in rare and complex cardiac diseases (ERN) designated by EU commission.

Department of Cardiology. Hospital Universitario Puerta de Hierro Majadahonda

Joaquín Rodrigo, 2. 28222 Majadahonda, Madrid

**Full Professor.** Start: March 2022

Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid

Melchor Fernández Almagro 3

28029 Madrid, Spain

## Other Positions

| | |
|---|---|
| 2019-present | **Adjunct Professor.** Universidad Autónoma de Madrid (UAM), Madrid, Spain. |
| 2019-present | **Visiting Professor**. Universidad Francisco de Vitoria, Madrid, Spain. |
| 2013-2022 | **Visiting Scientist.** Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid |
| 2017-2019 | **Adjunct Professor**. Universidad Francisco de Vitoria, Madrid, Spain. |
| 2008-2009 | **Clinical Research Fellow**. Inherited Cardiac Diseases Unit. The Heart Hospital. University College London, London, UK. |
| 2004-2008 | **Resident in Cardiology**, Clínica Puerta de Hierro, Madrid. |
| 2001-2002 | **Research Associate**, Dept. of Internal Medicine, Hospital La Paz. Universidad Autónoma, Madrid. |

| | |
|---|---|
| Junio 2000-Sept 2000 | **Research fellow**, Dept. of Rheumatology, University of Chicago, EEUU. |
| Junio 1999-Sept 1999 | **Research fellow**. Immunology Department, School of Medicine. Universidad Complutense, Madrid. |
| Junio 1998-Sept 1998 | **Research fellow**. Biochemistry Department, School of Medicine. Universidad Autónoma, Madrid. |

## Narrative biosketch:

My career has been focused in understanding myocardial diseases, from basic studies unravelling genetics to the translation of therapeutic targets into the clinical arena. My motivation has always been to improve the life of patients with inherited cardiomyopathies and prevent their families from suffering devastating complications like sudden cardiac death or end-stage heart failure.

I am the head of the Heart Failure and Inherited cardiac diseases Section at Hospital Puerta de Hierro and, since 2022, I am also Full Professor Group Leader in Hereditary Cardiomyopathies at the Spanish National Center for Cardiovascular Research (CNIC). I have been the director of the Inherited cardiac diseases unit at Hospital Puerta de Hierro since its creation in 2009 and under my leadership this unit has grown to become one of the most important European centers in the field of amyloidosis and genetic heart diseases. The unit was designated a National Reference Center (CSUR) in 2013 and a European Reference Center (ERN) in 2017.

Upon completing my cardiology training, I pursued a fellowship in inherited cardiac diseases at The Heart Hospital, University College London (UCL). During my undergraduate period I had previously undertaken research positions in genetic labs at the University of Chicago, Universidad Autónoma de Madrid (UAM), and Universidad Complutense de Madrid (UCM). My doctoral thesis, in which I described for the first time mutations in desmosomal genes as a cause of Dilated Cardiomyopathy (DCM), was awarded the Extraordinary Doctoral Award by UAM and the 'Ulysses' Prize for the best doctoral thesis published in Spain in 2011.

Multiple distinctions have been granted to me, including the First Research Award from Hospital La Paz (2004), the Runner-up Ministry of Health Award for the Best Resident Physician (2009), the Dr. Cardeñosa Award from the Royal National Academy of Medicine (2011), the Ulysses Prize (2012), the Scientific Innovation Award from the Pfizer Foundation (2019), and the 20th Research Prize from the Medical Association of Córdoba (2022).

At scientific societies I have served as Coordinator of the Inherited Cardiac Diseases Working Group of the Spanish Society of Cardiology (2013–2016), and as a Board Member of the European Society of Cardiology (ESC) Myocardial and Pericardial Diseases Working Group (2014-2018), the ESC Council on Basic Cardiovascular Science (2014-2018), the ESC Council of Cardio-Oncology (2018-2020) and the ESC Council of Cardiovascular Genomics (2022-2024). Currently I am Chairman of the HFA Cardiac Amyloidosis committee and member of the HFA Hypertrophic cardiomyopathy committee for the period 2024 to 2026.

I was the lead author of the 2021 ESC position paper on the diagnosis and treatment of cardiac amyloidosis (Garcia-Pavia, et al. Eur Heart J 2021), the 2026 ESC HFA clinical consensus on the non-amyloid specific treatment for TTR cardiac amyloidosis (Garcia-Pavia et al. Eur Heart J 2026) and the 2025 ESC HFA consensus on clinical care of family members of patients with

DCM (Verdonschot et al. Eur Heart J. 2025) and participated as an author of the first ESC Guidelines in cardiomyopathies (2023).

I have authored 32 book chapters (including the cardiomyopathies chapter at Farreras-Rozman book of Internal Medicine and the cardiac amyloidosis chapter at Fuster & Hurst's The Heart), over 300 publications, and have received 19,937 citations (H-index 66).

My scientific production includes 47 articles as corresponding author in top-tier (1st decile) journals, including two original articles as first and corresponding author in The New England Journal of Medicine published in 2023 and 2025 (only active Spanish researcher with two original articles published as first author at NEJM). I have published also as corresponding author 24 articles in the three leading cardiovascular journals: 12 in the Journal of the American College of Cardiology, 9 in the European Heart Journal, and 3 in Circulation. I have also co-authored studies published in The New England Journal of Medicine (4 original articles), Nature Medicine, and The Lancet.

The research lines of my group are ATTR amyloidosis and inherited cardiomyopathies. In the ATTR field we published in 2015 a seminal article (Gonzalez-Lopez et al. Eur Heart J 2015, 1,019 citations) that changed the diagnostic approach to ATTR, a disease that, until this publication, was ignored as a common cause of heart failure. I also led the first study using a monoclonal antibody to remove amyloid from the heart, opening up a new therapeutic option to improve and even cure this devastating disease which is now being tested in a Phase 3 trial (Garcia-Pavia et al. N Eng J Med 2023).

Our scientific contributions in the field of genetic cardiac diseases have also been of great significance. We have described new genetic causes of cardiomyopathies (Heart 2011, JACC 2016, Circulation 2023, Circ Heart Fail 2024), were the first to describe the involvement of genetics in toxic DCM (JACC 2018 and Circulation 2019) and reported several studies on the differential clinical course and management of cardiac diseases according to the underlying genotype (JACC 2017, 2018, 2020, 2021, 2022, 2022 and 2024, and Eur Heart J 2025). I am deeply involved in developing new therapies to treat ATTR and cardiomyopathies and have led seminal studies with cardiac myosin inhibitors to treat Hypertrophic cardiomyopathy (Garcia-Pavia et al, Eur Heart J 2024 and Garcia-Pavia et al N Eng J Med 2025).

Furthermore, I am Group Leader, and Coordinator of the Genetic Diseases Program at CIBERCV, the Spanish research collaborative network that groups the 40 leading groups in cardiovascular research in Spain. I have received continuous funding as Principal Investigator from ISCIII; the Spanish Ministry of Economy/Science and private Foundations, as well as European Union funding (3 EU funded projects).

Currently I serve as Principal Investigator for 4 ongoing trials in the field of cardiomyopathies and amyloidosis. Two of these trials are independent academic clinical trials funded by the Spanish ISCIII: the **EARLY-GENE trial** (NCT05321875) in which 41 Spanish and Dutch centers are evaluating whether preventive treatment with candesartan prevents the development of DCM in non-affected genetic carriers and the **SPANISH-1 trial** (NCT06055504) which evaluates if a personalized strategy for SCD prevention based in genetics and CMR features is superior to usual care in patients with non-ischemic DCM. In addition, I am a member of the steering committees of 8 international trials in the field of amyloidosis and genetic cardiac diseases.

Additionally, I am the author of 5 patents for detecting a genetic subtype of DCM and for treating DCM genetic subtypes through gene therapy.

My dedication for continuous training and mentoring pupils has been intense, I have supervised 12 doctoral theses and, for the last 15 years, I have led a fellowship program in Inherited cardiac diseases that has trained numerous cardiologists who now lead the inherited cardiac diseases units at many of the most important Spanish hospitals. I believe this has contributed decisively to the development of this field of cardiology in Spain and ultimately is fostering the next generation of professionals committed to improving patients' lives, as we collectively continue expanding the limits of knowledge.

## Patents:

**Method to detect predisposition to dilated cardiomyopathy. P.201530298.** Registered:10 March 2015. Obtained: 10/07/2017. Inventors: P Garcia-Pavia, E Lara-Pezzi, S Cuenca, L Padron

**Method for improving cardiac function in arrhythmogenic right ventricular cardiomyopathy type 5.** Priority date: 08/01/2025. Application number: EP25382006.2 (patent pending). Inventors: Byrne, B. J.; Corti, M.; Lara Pezzi, E.; Lalaguna Díaz, L.; García-Pavía, P.

**Methods and compositions for treating TMEM43 related cardiomyopathy with a viral vector.** US2025/0195695 A1. Publication date: 19/Jun/2025. Inventors: Byrne, B. J.; Corti, M.; Lara Pezzi, E.; Lalaguna Díaz, L.; García Pavía, P. Ownership: CNIC: 50%; H. Puerta de Hierro: 20%; U. Florida: 30%. License option for Ventura Life Sciences executed.

**A CRISPR activation system and its use in the treatment and/or prevention of cardiomyopathy.** Publication date: 29/Aug/2025. Inventors: Lara Pezzi, E.; CAÑAS ÁLVARO R; García Pavía, P. CHAVEZ A. Ownership: CNIC: 80%; U California 20%.

**Methods and in vitro uses of biomarkers for identifying subjects at risk of having transthyretin amyloidosis cardiomyopathy (ATTR-CM).** Priority date: 23/10/2025. Inventors: García Pavía, P; Camara AI; Ochoa JP; Martin P. Ownership: Fundación para la Investigación Biomédica del Hospital Universitario Puerta de Hierro Majadahonda (55%); CNIC (45%).

## Peer recognition

**Indicators of Scientific Productivity [March 2026]**

- Total publications: 349, 195 in 1st quartile (Q1), 144 in 1st decile (D1).

- Publications as main author (senior/corresponding or 1st author): 131 (79 in Q1, 47 in D1).

- Total citations: 19,937 (WoS). Citations after excluding Guidelines and Position Papers: 17,025 (WoS).

- **H-index: 66**

## Funded research projects

During his research career, Dr. García-Pavía has participated in **more than 50 projects** funded by national and international, public and private agencies. He has received continuous funding as **Principal Investigator (PI) since 2011, leading 27 projects** with a total accumulated funding of **€6,352,514**. This includes funding from the Instituto de Salud Carlos III (ISCIII) (8 projects); the Ministry of Science, Innovation and Universities (CPP2024-011665, PLEC2022-009235); the Ministry of Economy/Science (SAF2015-71863-REDT); Fundación Mutua Madrileña (2014); Fundación Isabel Gemio (2015); the Spanish Society of Cardiology (SEC) (2008, 2014);

Fundación Eugenio Rodríguez Pascual (2023); as well as funding from 3 European projects (ERA-NET-CVD 2017, HORIZON-EIC-2022-PATHFINDERCHALLENGES-01 2023, ERA4Health – CARDINNOV 2023).

Of the **9 ongoing projects** where he is PI, 7 are funded by public institutions: 2 under the European HORIZON program, 4 from the ISCIII, and 1 from the Ministry of Science, Innovation and Universities. The total funding obtained from these competitive calls is **€3,515,286.70**. Furthermore, he is the principal investigator of 2 active projects funded by private institutions (Fundación Eugenio Rodríguez Pascual and Alnylam) with a combined funding of €98,942.50.

## Supervision

**- Doctoral Thesis:** 12 PhD thesis supervised. All qualified with honors. Supervising 8 PhD thesis currently.

- **Previous Fellows (current work):** Esther Gonzalez-Lopez (Inherited cardiac diseases, Hospital Puerta de Hierro); Sofia Cuenca (Inherited cardiac diseases, Hospital La Princesa); Fernando Dominguez (Inherited cardiac diseases, Hospital Puerta de Hierro); Angela Lopez-Sainz (Hospital Clinic and transitioned to industry, currently at Medical department of BMS); Alejandra Restrepo-Cordoba (Inherited cardiac diseases, Hospital Clinico San Carlos); Silvia Vilches (Inherited cardiac diseases, Hospital 12 de Octubre); Aitor Hernandez (Inherited cardiac diseases, Clinica Universitaria Navarra); Luis Escobar-Lopez (Hospital Donosti and transitioned to industry, currently at Medical department of BMS); Fernando de Frutos (Inherited cardiac diseases, Hospital Bellvitge Barcelona); Eva Cabrera (Inherited cardiac diseases, Hospital Virgen de la Arrixaca, Murcia); Belén Peiró (Inherited cardiac diseases, Hospital Miguel Servet Zaragoza); Nerea Mora (Inherited cardiac diseases, Complejo Hospitalario Navarra); Daniel de Castro (Fundación Jimenez Diaz).

## Selected Publications


1. **Garcia-Pavia P** *, Gonzalez-Lopez E, Anderson LJ, Cappelli F, Damy T, Fontana M, Gonzalez-Costello J, Jurcut R, Lairez O, van der Meer P, Merlo M, Perlini S, Bayes-Genis A*. Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association. Eur Heart J. 2026;47:22-36.. * Co-corresponding authors.

2. **Garcia-Pavia P***, Maron MS, Masri A, Merkely B, Nassif ME, Peña-Peña ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Hegde SM, Lakdawala NK, Lewis GD, Mann A, Miao ZM, Nair A, Poulsen SH, Reant P, Schulze PC, Solomon SD, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA. Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. 2025;393:949-960. * Corresponding author

3. Verdonschot JAJ*, Kaski JP, Asselbergs FW, Behr ER, Charron P, Dawson D, Haugaa KH, Kuchynka P, Lopes LR, Mazzanti A, Monserrat L, Pantazis A, Prasad SK, Schunkert H, Seferovic PM, Sheppard MN, Sinagra G, van Tintelen JP, Tome Esteban MT, Heymans SRB, **Garcia-Pavia P***. Clinical care of family members of patients with dilated cardiomyopathy. Eur Heart J. 2025 Sep 3:ehaf571. * Co-corresponding authors.

4. Gonzalez-Lopez E, Maurer MS, **Garcia-Pavia P**. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025 46:999-1013.

5. Mora-Ayestarán N, Ochoa JP, Gómez-González C, Navarro-Peñalver M, Gallego-Delgado M, Larrañaga-Moreira JM, Robles-Mezcua A, Basurte-Elorz MT, Rodriguez-Palomares JF, Climent-Paya V, Jiménez-Jaímez J, Mogollón-Jiménez MV, García-Granja PE, García-Álvarez A, Peña-Peña ML, Alvarez Barredo M, Ripoll-Vera T, Palomino-Doza J, Bayes-Genis A, Tirón C, Fernández AI, Sabater-Molina M, Toranzo I, Crespo-Leiro MG, Doncel-Abad V, Lacuey-Lecumberri G, Limeres-Freire J, García-Álvarez MI, Cabrera-Borrego E, Kounka-Ait El Maalem Z, Vilches S, González-López E, Villacorta E, García-Pinilla JM, Barriales-Villa R, Gimeno-Blanes JR, **Garcia-Pavia P,*** Domínguez F.* Arrhythmic genotypes in dilated cardiomyopathy and risk of advanced heart failure. Eur Heart J. 2025;46:5222-5233.* Co-corresponding

6. Cabrera-Romero E, Ochoa JP, Barriales-Villa R, Bermúdez-Jiménez FJ, Climent-Payá V, Zorio E, Espinosa MA, Gallego-Delgado M, Navarro-Peñalver M, Arana-Achaga X, Piqueras-Flores J, Espejo-Bares V, Rodríguez-Palomares JF, Lacuey-Lecumberri G, López J, Tiron C, Peña-Peña ML, García-Pinilla JM, Lorca R, Ripoll-Vera T, Díez-López C, Mogollon MV, García-Álvarez A, Martínez-Dolz L, Brion M, Larrañaga-Moreira JM, Jiménez-Jáimez J, García-Álvarez MI, Vilches S, Villacorta E, Sabater-Molina M, Solla-Ruiz I, Royuela A, Domínguez F, Mirelis JG, **Garcia-Pavia P.** Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives. J Am Coll Cardiol. 2024;83:1640-1651.

7. Gonzalez-Lopez E, McPhail ED, Salas-Anton C, Dominguez F, Gertz MA, Dispenzieri A, Dasari S, Milani P, Verga L, Grogan M, Palladini G, **Garcia-Pavia P.** Histological Typing in Patients With Cardiac Amyloidosis. J Am Coll Cardiol. 2024;83:1085-99.

8. **Garcia-Pavia P***, Aus dem Siepen F, Donal E, Lairez O, van der Meer P, Kristen AV, Mercuri MF, Michalon A, Frost RJA, Grimm J, Nitsch RM, Hock C, Kahr PC, Damy T. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023; 389:239-250.* Corresponding author

9. Domínguez F, Lalaguna L, Martínez-Martín I, Piqueras-Flores J, Rasmussen TB, Zorio E, Giovinazzo G, Prados B, Ochoa JP, Bornstein B, González-López E, Velázquez-Carreras D, Pricolo MR, Gutiérrez-Agüera F, Bernal JA, Herrero-Galán E, Alegre-Cebollada J, Lara-Pezzi E, **García-Pavía P**. Titin Missense Variants as a Cause of Familial Dilated Cardiomyopathy. Circulation. 2023;147:1711-3.

10. Escobar-Lopez L, Ochoa JP, Royuela A, Verdonschot JAJ, Dal Ferro M, Espinosa MA, Sabater-Molina M, Gallego-Delgado M, Larrañaga-Moreira JM, Garcia-Pinilla JM, Basurte-Elorz MT, Rodríguez-Palomares JF, Climent V, Bermudez-Jimenez FJ, Mogollón-Jiménez MV, Lopez J, Peña-Peña ML, Garcia-Alvarez A, López-Abel B, Ripoll-Vera T, Palomino-Doza J, Bayes-Genis A, Brugada R, Idiazabal U, Mirelis JG, Dominguez F, Henkens MTHM, Krapels IPC, Brunner HG, Paldino A, Zaffalon D, Mestroni L, Sinagra G, Heymans SRB, Merlo M, **Garcia-Pavia P**. Clinical Risk Score to Predict Pathogenic Genotypes in Patients with Dilated Cardiomyopathy. J Am Coll Cardiol. 2022;80:1115-1126.

11. de Frutos F, Ochoa JP, Navarro-Peñalver M, Baas A, Bjerre JV, Zorio E, Méndez I, Lorca R, Verdonschot JA, García-Granja PE, Bilinska Z, Fatkin D, Fuentes-Cañamero ME, García-Pinilla JM, García-Álvarez MI, Girolami F, Barriales-Villa R, Díez-López C, Lopes LR, Wahbi K, García-Álvarez A, Rodríguez-Sánchez I, Rekondo-Olaetxea J, Rodríguez-Palomares JF, Gallego-Delgado M, Meder B, Kubanek M, Hansen FG, Restrepo-Córdoba MA, Palomino-Doza J, Ruiz-Guerrero L, Sarquella-Brugada G, Perez-Perez AJ, Bermúdez-Jiménez FJ, Ripoll-Vera T, Rasmussen TB, Jansen M, Sabater-Molina M, Elliot PM, **Garcia-Pavia P**.

Natural History of MYH7-related Dilated Cardiomyopathy. J Am Coll Cardiol. 2022; 80:1447-1461.

12. Escobar-Lopez L, Ochoa JP, Mirelis JG, Espinosa MÁ, Navarro M, Gallego-Delgado M, Barriales-Villa R, Robles-Mezcua A, Basurte-Elorz MT, Gutiérrez García-Moreno L, Climent V, Jiménez-Jaimez J, Mogollón-Jiménez MV, Lopez J, Peña-Peña ML, García-Álvarez A, Brion M, Ripoll-Vera T, Palomino-Doza J, Tirón C, Idiazabal U, Brögger MN, García-Hernández S, Restrepo-Córdoba MA, Gonzalez-Lopez E, Méndez I, Sabater M, Villacorta E, Larrañaga-Moreira JM, Abecia A, Fernández AI, García-Pinilla JM, Rodríguez-Palomares JF, Gimeno-Blanes JR, Bayes-Genis A, Lara-Pezzi E, Domínguez F, **Garcia-Pavia P**. Association of Genetic Variants With Outcomes in Patients With Nonischemic Dilated Cardiomyopathy. J Am Coll Cardiol. 2021;78:1682-1699.

13. **Garcia-Pavia P***, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2021;42:1554-1568 .* corresponding author

14. Lopez-Sainz A, Dominguez F, Lopes LR, Ochoa JP, Barriales-Villa R, Climent V, Linschoten M, Tiron C, Chiriatti C, Marques N, Rasmussen TB, Espinosa MÁ, Beinart R, Quarta G, Cesar S, Field E, Garcia-Pinilla JM, Bilinska Z, Muir AR, Roberts AM, Santas E, Zorio E, Peña-Peña ML, Navarro M, Fernandez A, Palomino-Doza J, Azevedo O, Lorenzini M, García-Álvarez MI, Bento D, Jensen MK, Méndez I, Pezzoli L, Sarquella-Brugada G, Campuzano O, Gonzalez-Lopez E, Mogensen J, Kaski JP, Arad M, Brugada R, Asselbergs FW, Monserrat L, Olivotto I, Elliott PM, **Garcia-Pavia P**. Clinical Features and Natural History of PRKAG2 Variant Cardiac Glycogenosis. J Am Coll Cardiol. 2020;76:186-197.

15. **Garcia-Pavia P*,** Kim Y, Alejandra Restrepo-Cordoba M, Lunde IG, Wakimoto H, Smith AM, Toepfer CN, Getz K, Gorham J, Patel P, Ito K, Willcox JA, Arany Z, Li J, Owens AT, Govind R, Nuñez B, Mazaika E, Bayes-Genis A, Walsh R, Finkelman B, Lupon J, Whiffin N, Serrano I, Midwinter W, Wilk A, Bardaji A, Ingold N, Buchan R, Tayal U, Pascual-Figal DA, de Marvao A, Ahmad M, Garcia-Pinilla JM, Pantazis A, Dominguez F, Baksi AJ, O'Regan DP, Rosen SD, Prasad SK, Lara-Pezzi E, Provencio M, Lyon AR, Alonso-Pulpon L, Cook SA, DePalma SR, Barton PJR, Aplenc R, Seidman JG, Ky B, Ware JS, Seidman CE*. Genetic Variants Associated with Cancer Therapy-Induced Cardiomyopathy. Circulation 2019;140:31-41. *Co-corresponding authors.

16. Padrón-Barthe L, Villalba-Orero M, Gómez-Salinero JM, Domínguez F, Román M, Larrasa-Alonso J, Ortiz-Sánchez P, Martínez F, López-Olañeta M, Bonzón-Kulichenko E, Vázquez J, Martí-Gómez C, Santiago DJ, Prados B, Giovinazzo G, Gómez-Gaviro MV, Priori S, **Garcia-Pavia P*,** Lara-Pezzi E*. Severe cardiac dysfunction and death caused by ARVC type 5 is improved by inhibition of GSK3B. Circulation 2019;140:1188-1204. *Co-corresponding authors.

17. Ware JS, Amor-Salamanca A, Tayal U, Govind R, Serrano I, Salazar-Mendiguchía J, García-Pinilla JM, Pascual-Figal D, Nuñez J, Guzzo-Merello G, Gonzalez-Vioque E, Bardaji A, Manito N, López-Garrido MA, Padron-Barthe L, Edwards E, Whiffin N, Walsh R, Buchan RJ, Midwinter W, Wilk A, Prasad S, Pantazis A, O'Regan DP, Alonso-Pulpon L, Cook SA, Lara-Pezzi E, Barton P, **Garcia-Pavia P.** A genetic etiology for alcohol-induced cardiac toxicity. J Am Coll Cardiol. 2018;71:2293-302.

18. Zegri-Reiriz I, de Alarcón A, Muñoz P, Martínez Sellés M, González-Ramallo V, Miro JM, Falces C, Gonzalez Rico C, Kortajarena Urkola X, Lepe JA, Rodriguez Alvarez R, Reguera Iglesias JM, Navas E, Dominguez F, **Garcia-Pavia P**. Infective endocarditis in bicuspid aortic valve and mitral valve prolapse. J Am Coll Cardiol. 2018;71:2731–40.

19. Domínguez F, Cuenca S, Bilińska Z, Toro R, Villard E, Barriales-Villa R, Ochoa JP, Asselbergs F, Sammani A, Franaszczyk M, Akhtar M, Coronado-Albi MJ, Rangel-Sousa D, Rodriguez-Palomares JF, Jiménez-Jáimez J, Garcia-Pinilla JM, Ripoll-Vera T, Mogollón-Jiménez MV, Fontalba-Romero A, Garcia-Medina D, Palomino-Doza J, de Gonzalo-Calvo D, Cicerchia M, Salazar-Mendiguchia J, Salas C, Pankuweit S, Hey TM, Mogensen J, Barton PJ, Charron P, Elliott P, **Garcia-Pavia P**. Dilated Cardiomyopathy Due to BLC2-Associated Athanogene 3 (BAG3) Mutations. J Am Coll Cardiol. 2018;72:2471-2481.

20. González-López E, Gagliardi C, Dominguez F, Quarta CC, de Haro-del Moral FJ, Milandri A, Salas C, Cinelli M, Cobo-Marcos M, Lorenzini M, Lara-Pezzi E, Foffi S, Alonso-Pulpon L, Rapezzi C, **Garcia-Pavia P**. Clinical characteristics of wild-type transthyretin cardiac amyloidosis – Disproving myths. Eur Heart J 2017;38:1895–1904.

21. Amor-Salamanca A, Castillo S, Gonzalez-Vioque E, Dominguez F, Quintana L, Lluís-Ganella C, Escudier JM, Ortega J, Lara-Pezzi E, Alonso-Pulpon L, **Garcia-Pavia P**. Genetically Confirmed Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome. J Am Coll Cardiol. 2017;70:1732-40.

22. Gallego-Delgado M, Delgado JF, Brossa-Loidi V, Palomo J, Marzoa-Rivas R, Perez-Villa F, Salazar-Mendiguchía J, Ruiz-Cano MJ, Gonzalez-Lopez E, Padron-Barthe L, Bornstein B, Alonso-Pulpon L, **Garcia-Pavia P**. Idiopathic restrictive cardiomyopathy is primarily a genetic disease. J Am Coll Cardiol 2016;67:3021-3.

23. Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro FJ, Cobo-Marcos M, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, **Garcia-Pavia P**. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585-94.

24. **Garcia-Pavia P*,** Syrris P, Salas C, Evans A, Mirelis JG, Cobo-Marcos M, Vilches C, Bornstein B, Segovia J, Alonso-Pulpon L, Elliott PM. Desmosomal protein gene mutations in patients with idiopathic dilated cardiomyopathy undergoing cardiac transplantation: A clinicopathological study. Heart 2011;97:1744-52.* corresponding author

25. **Garcia-Pavia P***, Vázquez ME, Segovia J, Salas C, Avellana P, Gómez-Bueno M, Vilches C, Gallardo ME, Garesse R, Molano J, Bornstein B, Alonso-Pulpon L. Genetic basis of end-stage Hypertrophic Cardiomyopathy. Eur J Heart Fail 2011;13:1193-201.* corresponding author